---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-25-000045"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T10:49:50.100950+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Curis Q1 net loss $10.6M, appoints Dr. Hamdy CMO, emavusertib progress

## Summary
- Net loss $10.6M ($1.25/share); cash $20.3M; runway into Q4 2025.
- Revenue $2.4M from Genentech/Roche Erivedge royalties.
- Appointed Dr. Ahmed Hamdy (ex-Pharmacyclics, Acerta) as CMO.
- FDA & EMA meetings support accelerated approval path for emavusertib in PCNSL.
- Completed registered direct offering and private placement with net proceeds ~$8.8M.

## SEC filing metadata
- accession: 0001108205-25-000045
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820525000045/0001108205-25-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820525000045/cris-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-25-000045
- JSON: https://secwatch.observer/filing/0001108205-25-000045.json
- Plain text: https://secwatch.observer/filing/0001108205-25-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.